Introduction
Methods
Eligibility criteria
Search strategy
Study selection
Data extraction
Reporting quality assessment
Item no | Specifics |
---|---|
Q1 | Whether the feature of ITCWM was presented in Title? |
Q2 | Whether the eligibility criteria of participants included both Chinese and western medical diagnosis in Methods of Abstract? |
Q3 | Whether the study objectives or hypotheses were focused on the ITCWM interventions in Abstract? |
Q4 | Whether the outcome measures included both TCM and WM related endpoints in Abstract? |
Q5 | Whether the effect of studied ITCWM interventions was reported in Conclusion of Abstract? |
Q6 | Whether the feature or design of ITCWM study were reflected in Keywords? |
Q7 | Whether the reason/rationale about ITCWM intervention for the study design was reported in the Background? |
Q8 | Whether the objectives or hypotheses were focused on the ITCWM interventions in the Background? |
Q9 | Whether the eligibility criteria of participants included both Chinese and western medical diagnosis in Methods? |
Q10 | Whether the specific information of disease (e.g., classification of disease, treatment points, stages of diseases) of the ITCWM was reported in Methods? |
Q11 | Whether the specific type/way of integration of TCM and WM interventions (such as overlying, one-after-another, or add-on design) was reported in Methods? |
Q12 | In the ITCWM group, whether TCM intervention(s) was reported with sufficient details to allow replication, including how and when they were administered? |
Q13 | In the ITCWM group, whether WM intervention(s) was reported with sufficient details to allow replication, including how and when they were administered? |
Q14 | In the control group, whether sufficient details were reported to allow replication? |
Q15 | Whether the outcome measures included both TCM and WM related endpoints in Methods? |
Q16 | For the studies with open label, whether any reasons or explanations for such design was reported? |
Q17 | In the control group(s), did the placebo of WM invention(s) was included? If so, whether sufficient details were provided? |
Q18 | In the control group(s), did the placebo of TCM invention(s) was included? If so, whether sufficient details were provided? |
Q19 | In the section of Results, whether any information about the participants exposed to ITCWM treatment prior to recruitment was mentioned in the baseline data? |
Q20 | Whether interpretation and significance of studied ITCWM interventions for the disease was reported in Discussion? |
Q21 | Whether any potential conflicts of interests were clearly reported? |
Data analysis
Results
Search result
Characteristics of included trials
Characteristic | N (%) |
---|---|
Language of publications | |
English | 9 (2.00) |
Chinesea | 442 (98.00) |
Diagnostic criteria | |
Single western medicine diagnosis | 49 (10.86) |
Both TCM and western medicine diagnosis | 402 (89.14) |
Including TCM Patternb | 390 (97.01) |
Types of AP | |
Stable | 225 (49.89) |
Unstable | 115 (25.50) |
Othersc | 111 (24.61) |
Sample size | |
≤ 50 | 12 (2.66) |
51–100 | 350 (77.61) |
101–300 | 85 (18.85) |
> 300 | 4 (0.89) |
Number of assigned groupsd | |
2 | 438 (97.12) |
3 | 7 (1.55) |
4 | 6 (1.33) |
Types of TCM interventionse | |
Chinese herbal formula | 389 (86.25) |
Chinese single herb | 10 (2.22) |
Complex intervention | 25 (5.54) |
External therapy | 27 (5.99) |
Type of western medicine interventions | |
Pharmacological treatment | 439 (97.34) |
Non-pharmacological treatmentf | 10 (2.22) |
Not specificg | 2 (0.44) |
Treatment duration | |
Median (IQR) /day | 42 (28–56) |
Follow-up duration | |
Median (IQR) /day | 117 (30–180) |
Outcomes | |
Including TCM-related indicators | 390 (86.47) |